RECURSION PHARMACEUTICALS (RXRX) stock: insider trades, news & valuation
Heavy selling
Close · Oct 9, 2026
$4.36
+10.4% on the day
-26.2% over 12 months
52-week range $2.84 – $6.79
Share price and insider trades
RXRX closeInsider buyInsider sale
Bought, 12 months$0
Sold, 12 months$8.8M
Insiders buying0
Insiders selling6
RECURSION PHARMACEUTICALS insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 6 sold $8.8M of RXRX stock on the open market.
Get emailed when insiders cluster-buy stocks like RXRX
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
RXRX insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | $367K | 2 |
| Q3 2026 | — | 0 | $435K | 4 |
| Q2 2026 | — | 0 | $1.1M | 11 |
| Q1 2026 | — | 0 | $3.4M | 11 |
| Q4 2025 | — | 0 | $3.5M | 9 |
Valuation, profit and volume
P/E (trailing)n/aSector median —
Market value—
Profit margin—Revenue growth —
Volume vs. 50-day2.7×Last 5 sessions
Insiders' paper profit—On all tracked purchases —
Summary
Over the past 12 months, 0 RECURSION PHARMACEUTICALS, INC. insiders reported open-market purchases totaling $0, while 6 insiders reported sales totaling $8.8M. 37 of 37 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Oct 7SEC | Blake BorgesonDirector | Sell Plan | 50,0006,108,287 held (−1%) | $4.84 | $242K | -9.9% | — |
| Oct 7SEC | Robert HershbergDirector | Sell Plan | 25,000162,156 held (−13%) | $5.00 | $125K | -12.8% | — |
| Sep 10SEC | Najat KhanCEO, President | Sell Plan | 22,4082,072,890 held (−1%) | $3.52 | $79K | +23.9% | — |
| Sep 2SEC | Blake BorgesonDirector | Sell Plan | 30,0006,158,287 held (−0%) | $3.34 | $100K | +30.5% | — |
| Aug 6SEC | Blake BorgesonDirector | Sell Plan | 30,0006,188,287 held (−0%) | $3.25 | $98K | +34.2% | — |
| Jul 9SEC | Blake BorgesonDirector | Sell Plan | 40,0006,218,287 held (−1%) | $3.96 | $158K | +10.1% | — |
| Jun 22SEC | Namandje BumpusDirector | Sell Plan | 3,963127,632 held (−3%) | $3.18 | $13K | +37.1% | — |
| Jun 5SEC | Christopher GibsonDirector | Sell Plan | 40,000883,735 held (−4%) | $3.62 | $145K | +20.4% | — |
| Jun 5SEC | Najat KhanCEO, President | Sell Plan | 23,5882,175,796 held (−1%) | $3.58 | $84K | +21.8% | — |
| Jun 4SEC | Blake BorgesonDirector | Sell Plan | 30,0006,169,863 held (−0%) | $3.68 | $110K | +18.5% | — |
| Jun 4SEC | Namandje BumpusDirector | Sell Plan | 4,38643,171 held (−9%) | $3.54 | $16K | +23.2% | — |
| May 27SEC | Christopher GibsonDirector | Sell Plan | 40,000883,735 held (−4%) | $3.08 | $123K | +41.6% | — |
| May 8SEC | Christopher GibsonDirector | Sell Plan | 40,000926,556 held (−4%) | $3.37 | $135K | +29.4% | — |
| May 7SEC | Blake BorgesonDirector | Sell Plan | 30,0006,199,863 held (−0%) | $3.52 | $106K | +23.9% | — |
| Apr 24SEC | Christopher GibsonDirector | Sell Plan | 40,000906,556 held (−4%) | $3.61 | $144K | +20.8% | — |
| Apr 8SEC | Christopher GibsonDirector | Sell Plan | 40,000906,556 held (−4%) | $3.10 | $124K | +40.6% | — |
| Apr 8SEC | Blake BorgesonDirector | Sell Plan | 30,0006,229,863 held (−0%) | $3.10 | $93K | +40.6% | — |
| Mar 25SEC | Christopher GibsonDirector | Sell Plan | 40,000906,556 held (−4%) | $3.25 | $130K | +34.2% | — |
| Mar 18SEC | Ben R TaylorCFO | Sell Plan | 7,9561,180,318 held (−1%) | $3.39 | $27K | +28.6% | — |
| Mar 11SEC | Najat KhanCEO, President | Sell Plan | 28,2982,262,085 held (−1%) | $3.35 | $95K | +30.1% | — |
| Mar 4SEC | Blake BorgesonDirector | Sell Plan | 170,0006,259,863 held (−3%) | $3.46 | $588K | +26.0% | — |
| Feb 19SEC | Christopher GibsonDirector | Sell Plan | 40,000906,556 held (−4%) | $3.46 | $138K | +26.0% | — |
| Feb 19SEC | Ben R TaylorCFO | Sell Plan | 13,4261,195,349 held (−1%) | $3.08 | $41K | +41.6% | — |
| Feb 6SEC | Blake BorgesonDirector | Sell Plan | 220,0006,429,863 held (−3%) | $4.20 | $924K | +3.8% | — |
| Feb 6SEC | Christopher GibsonDirector | Sell Plan | 40,000913,839 held (−4%) | $4.12 | $165K | +5.8% | — |
| Jan 22SEC | Christopher GibsonDirector | Sell Plan | 40,000913,839 held (−4%) | $4.47 | $179K | -2.5% | — |
| Jan 8SEC | Blake BorgesonDirector | Sell Plan | 220,0006,649,863 held (−3%) | $4.36 | $959K | +0.0% | — |
| Jan 7SEC | Christopher GibsonDirector | Sell Plan | 40,000933,839 held (−4%) | $4.25 | $170K | +2.6% | — |
| Dec 30SEC | Ben R TaylorCFO | Sell Plan | 21,383761,550 held (−3%) | $4.18 | $89K | +4.3% | — |
| Dec 29SEC | Najat KhanChief R&D Commercial Officer | Sell Plan | 124,403611,135 held (−17%) | $4.41 | $549K | -1.1% | — |
| Dec 19SEC | Christopher GibsonCEO | Sell Plan | 40,000913,839 held (−4%) | $4.50 | $180K | -3.1% | — |
| Dec 5SEC | Christopher GibsonCEO | Sell Plan | 40,000933,839 held (−4%) | $4.63 | $185K | -5.8% | — |
| Dec 4SEC | Blake BorgesonDirector | Sell Plan | 220,0006,869,863 held (−3%) | $4.37 | $961K | -0.2% | — |
| Nov 19SEC | Christopher GibsonCEO | Sell Plan | 40,000913,839 held (−4%) | $4.16 | $166K | +4.8% | — |
| Nov 6SEC | Christopher GibsonCEO | Sell Plan | 40,000974,229 held (−4%) | $5.21 | $208K | -16.3% | — |
| Oct 24SEC | Christopher GibsonCEO | Sell Plan | 100,000954,229 held (−9%) | $5.70 | $570K | -23.5% | — |
| Oct 10SEC | Christopher GibsonCEO | Sell Plan | 100,000974,229 held (−9%) | $6.04 | $604K | -27.8% | — |
Insiders at RECURSION PHARMACEUTICALS, INC.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Blake BorgesonDirector | — | $4.3M | Oct 7, 2026 | — |
| Christopher GibsonDirector | — | $3.4M | Jun 5, 2026 | — |
| Najat KhanCEO, President | — | $807K | Sep 10, 2026 | — |
| Ben R TaylorCFO | — | $158K | Mar 18, 2026 | — |
| Robert HershbergDirector | — | $125K | Oct 7, 2026 | — |
| Namandje BumpusDirector | — | $28K | Jun 22, 2026 | — |
RXRX stock: common questions
Are RECURSION PHARMACEUTICALS, INC. insiders buying RXRX stock?
In the past 12 months, 0 insiders reported open-market purchases of RXRX worth $0.
Are RECURSION PHARMACEUTICALS, INC. insiders selling RXRX stock?
6 insiders reported sales worth $8.8M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is RXRX's 52-week range?
Over the past year RXRX has traded between $2.84 and $6.79. It last closed at $4.36 on Oct 9, 2026.